Persistence with biological drugs in patients treated in rheumatology practices in Germany
- 24 November 2018
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 39 (3) , 525-531
Abstract
The goal of this study was to investigate the persistence with biological drugs in patients treated in rheumatology practices in Germany. This study included patients diagnosed with rheumatoid arthritis (RA), psoriatic arthritis (PA), or ankylosing spondylitis (AS) who received a first prescription of biological drugs between 2008 and 2016 (index date) in 21 rheumatology practices in Germany (n = 4925; Disease Analyzer database). The main outcome measure was the rate of persistence within 5 years of the index date. Kaplan–Meier analyses were performed to study treatment persistence as a function of diagnosis, gender and age. A Cox proportional hazards regression model was used to estimate the relationship between non-persistence and diagnosis, gender, age, and comorbidities. After 5 years of follow-up, the rate of persistence was 31.8% in patients with RA, 35.2% in those with AS, and 33.2% in those with PA (log-rank p value = 0.028). Furthermore, 33.8% of men and 31.9% of women were persistent (log-rank p value = 0.035). The rate of persistence was 20.8%, 27.9%, 33.0%, 36.6%, 35.2%, and 32.0% in people aged ≤ 30, 31–40, 41–50, 51–60, 61–70, and > 70 years, respectively (log-rank p value = 0.002). The risk of discontinuation was lower in participants diagnosed with AS than in those diagnosed with RA [hazard ratio (HR) = 0.87; 95% confidence interval (CI) 0.79–0.96]. In addition, patients aged ≤ 30 years were more likely to discontinue their biological therapy than those aged > 70 years (HR = 1.29; 95% CI 1.10–1.52). Persistence with biological drugs was low after 5 years of follow-up in rheumatology practices.Keywords
This publication has 39 references indexed in Scilit:
- Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBITRheumatology, 2015
- Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in GermanyHealth Economics Review, 2014
- Persistence Rate With Subcutaneous Biologic Therapies in Patients With Ankylosing Spondylitis (As)Value in Health, 2014
- Comparative Persistence of the TNF Antagonists in Rheumatoid Arthritis – A Population-Based Cohort StudyPLOS ONE, 2014
- The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 studyAnnals of the Rheumatic Diseases, 2014
- What is the future of targeted therapy in rheumatology: biologics or small molecules?BMC Medicine, 2014
- Biologic therapy for autoimmune diseases: an updateBMC Medicine, 2013
- Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasisBritish Journal of Dermatology, 2009
- Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics RegisterArthritis Research & Therapy, 2009
- TNFα antagonist continuation rates in 442 patients with inflammatory joint diseaseJoint Bone Spine, 2007